Covid-19 creates uncertainty for Zealand Pharma drug against short bowel syndrome
Zealand Pharma's clinical development is running smoothly and the firm has sent a new drug candidate to clinic. Reversely, the resurgence of the Covid-19 pandemic has caused uncertainty regarding the time schedule for the firm's phase III drug Glepaglutide.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
As a biotech firm, Zealand Pharma's first priority during Covid-19 has been to ensure that its research and development program could continue with as few alterations as possible.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
